Bethel MA, et al. - This meta-analysis was performed to investigate overall cardiovascular efficacy for lixisenatide, liraglutide, semaglutide, and extended-release exenatide in patients with type 2 diabetes. Collected evidence indicated cardiovascular safety across all glucagon-like peptide-1 (GLP-1) receptor agonist cardiovascular outcome trials. Findings thereby suggested that drugs in this class could reduce 3-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual drugs, without significant safety concerns. GLP-1 receptor agonists had a favourable overall risk-benefit balance. This would allow the choice of drug to be individualised to each patient's needs.